
Opinion|Videos|February 19, 2025
Case 1 Presentation—KRAS-Mutated Metastatic NSCLC: First-Line Decision- Making
Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















